Details of the Drug

General Information of Drug (ID: DMQ7UL8)

Drug Name

Camostat

Synonyms

Camostat; 59721-28-7; camostate; Camostat [INN]; Camostatum [INN-Latin]; UNII-0FD207WKDU; CCRIS 7219; 4-(2-(2-(Dimethylamino)-2-oxoethoxy)-2-oxoethyl)phenyl 4-guanidinobenzoate; 0FD207WKDU; C20H22N4O5; Camostat (INN); Foipan; FOY 305; FOY-305; Dimethylcarbamoylmethyl 4-(4-guqnidinobenzoyloxy)phenylacetat; foypan; Camostatum; CHEMBL85164; camostate-mesilate; [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate; p-Guanidinobenzoic acid, ester with (p-hydroxyphenyl)acetic acid, ester with N

Indication

Disease Entry	ICD 11	Status	REF
Cystic fibrosis	CA25	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

398.4

Logarithm of the Partition Coefficient (xlogp)

1.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 10,400 +/- 1,400 mcgmin/L [2]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 87.1 +/- 29.5 mcg/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 40 min [2]
Clearance: The clearance of drug is 4.5-7.3 mL/min/kg [3]
Elimination: Camostat mesylate is 89.8-95.6% eliminated in the urine and 1.0-1.7% eliminated in the feces [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 3.8 - 4.7 hours [3]
Metabolism: The drug is metabolized via the carboxyesterate to the active 4-(4-guanidinobenzoyloxy) phenylacetate [3]
Vd: The volume of distribution (Vd) of drug is 0.34-1.31 L/kg [3]

Chemical Identifiers

Formula: C20H22N4O5
IUPAC Name: [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate
Canonical SMILES: CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N
InChI: InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23)
InChIKey: XASIMHXSUQUHLV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2536
ChEBI ID: CHEBI:135632
CAS Number: 59721-28-7
DrugBank ID: DB13729
TTD ID: D0Y6SQ
VARIDT ID: DR00883

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine protease unspecific (SP)	TTEMV5X	NOUNIPROTAC	Inhibitor	[4]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6432).
2	Ono Pharmaceutical: Foipan Camostat Mesilate Oral Tablets
3	Metabolic fate of 14C-camostat mesylate in man, rat and dog after intravenous administration. Xenobiotica. 1994 Jan;24(1):79-92. doi: 10.3109/00498259409043223.
4	Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens. 2009 Jan;27(1):181-9.
5	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.